Trial Profile

A Phase I, Open-Label Study of CLN-978 in Patients With Treatment-Refractory Rheumatoid Arthritis (RA)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLN 978 (Primary)
Indications Autoimmune disorders; Rheumatoid arthritis
Focus Therapeutic Use
Sponsors Cullinan Therapeutics

Most Recent Events

11 Jun 2025 Status changed from not yet recruiting to recruiting.
29 May 2025 Status changed from planning to not yet recruiting.
16 Apr 2025 According to Cullinan Therapeutics media release, the European Medicines Agency (EMA) approved the Clinical Trial Application (CTA) for CLN-978. Ricardo Grieshaber-Bouyer is global Principal Investigator for this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com